UY24613A1 - Formula de liberacion controlada que comprende venlafaxina - Google Patents

Formula de liberacion controlada que comprende venlafaxina

Info

Publication number
UY24613A1
UY24613A1 UY24613A UY24613A UY24613A1 UY 24613 A1 UY24613 A1 UY 24613A1 UY 24613 A UY24613 A UY 24613A UY 24613 A UY24613 A UY 24613A UY 24613 A1 UY24613 A1 UY 24613A1
Authority
UY
Uruguay
Prior art keywords
controlled release
formula including
release formula
venlafaxine
including venlafaxine
Prior art date
Application number
UY24613A
Other languages
English (en)
Inventor
Deborah M Sherman
John Clifton Clark
Stephen Andrew White
John Ulrick Lamer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21762972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY24613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of UY24613A1 publication Critical patent/UY24613A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

El presente invento se relaciona con una fórmula posológica y dosis unitaria de la misma, de clorhidrato de venlafaxina, un agente antidepresivo, de liberación prolongada sobre 24 horas, que ofrece un control de las concentraciones plasmáticas mejor que el de las fórmulas convencionales en tabletas que deberán administrarse dos o más veces al día, y que también se asocia con una incidencia más baja de náuseas y vómitos que las tabletas convencionales.
UY24613A 1996-03-25 1997-07-10 Formula de liberacion controlada que comprende venlafaxina UY24613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1400696P 1996-03-25 1996-03-25

Publications (1)

Publication Number Publication Date
UY24613A1 true UY24613A1 (es) 2000-09-29

Family

ID=21762972

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24613A UY24613A1 (es) 1996-03-25 1997-07-10 Formula de liberacion controlada que comprende venlafaxina

Country Status (34)

Country Link
EP (2) EP0797991B1 (es)
JP (2) JP4771565B2 (es)
KR (1) KR101096512B1 (es)
CN (2) CN1090018C (es)
AR (1) AR006519A1 (es)
AT (1) ATE257011T1 (es)
AU (1) AU727653B2 (es)
BR (1) BR9701304A (es)
CA (1) CA2199778C (es)
CO (1) CO4761054A1 (es)
CY (1) CY2442B1 (es)
CZ (1) CZ291637B6 (es)
DE (1) DE69727000T2 (es)
DK (1) DK0797991T3 (es)
EG (1) EG24198A (es)
ES (1) ES2210454T3 (es)
HK (1) HK1056686A1 (es)
HU (1) HU224617B1 (es)
IL (1) IL120382A (es)
IN (1) IN187337B (es)
NO (2) NO320355B1 (es)
NZ (1) NZ314442A (es)
PA (1) PA8426401A1 (es)
PE (1) PE57198A1 (es)
PL (2) PL195564B1 (es)
PT (1) PT797991E (es)
RU (1) RU2176912C2 (es)
SK (1) SK281530B6 (es)
SV (1) SV1997000015A (es)
TR (1) TR199700190A2 (es)
TW (1) TW493993B (es)
UA (1) UA44904C2 (es)
UY (1) UY24613A1 (es)
ZA (1) ZA972403B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
JP3379461B2 (ja) * 1998-08-06 2003-02-24 三菱電機株式会社 コア部材の積層金型装置、コア部材の積層方法および電動機
CA2374039C (en) * 1999-05-20 2011-01-11 Elan Corporation Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20020143211A1 (en) * 2000-10-19 2002-10-03 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
HUP0104872A3 (en) * 2001-11-13 2004-04-28 Egis Gyogyszergyar Nyilvanosan New polymorphic forms of venlafaxine, process for their preparation, pharmaceutical compositions containing them and their use
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
US20030190351A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Extended release venlafaxine formulations
EA011579B1 (ru) * 2003-02-07 2009-04-28 Актавис Груп Хф Композиция с пролонгированным высвобождением венлафаксина
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
ATE344659T1 (de) 2003-05-02 2006-11-15 Dexcel Ltd Tablettenzubereitung mit verlängerter freisetzung von venlafaxin
IN2003MU00504A (es) * 2003-06-05 2005-05-13 Alembic Ltd
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
SI1502587T1 (sl) 2003-07-30 2007-02-28 Pharmathen Sa Formulacija z zadrzevanim sproscanjem za Venlafaxin hidroklorid
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
DE10359154A1 (de) 2003-12-16 2005-07-28 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
NZ548504A (en) 2004-02-04 2009-03-31 Alembic Ltd Extended release coated microtablets of venlafaxine hydrochloride
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100463676C (zh) * 2004-11-11 2009-02-25 成都康弘药业集团股份有限公司 一种盐酸文拉法辛控释片制剂及其制备方法
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
ES2572180T3 (es) 2006-04-26 2016-05-30 Alphapharm Pty Ltd Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
KR100791194B1 (ko) * 2006-06-12 2008-01-02 코오롱제약주식회사 염산 벤라팍신의 경구 투여용 서방성 펠렛 및 그 제조방법
JP6045347B2 (ja) * 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
ES2673956T3 (es) 2011-01-31 2018-06-26 Serotech, Llc Régimen de dosificación, envase de dispensación de la medicación y usos de los mismos para el tratamiento del trastorno depresivo mayor
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PT1153603E (pt) * 1993-06-28 2007-01-31 Wyeth Corp Novos tratamentos utilizando derivados de fenetilamina
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada

Also Published As

Publication number Publication date
IL120382A (en) 2003-06-24
CZ291637B6 (cs) 2003-04-16
DK0797991T3 (da) 2004-04-05
CN1164389A (zh) 1997-11-12
EP0797991A1 (en) 1997-10-01
JPH107552A (ja) 1998-01-13
PE57198A1 (es) 1998-10-10
CZ77297A3 (en) 1997-11-12
EP2881110A1 (en) 2015-06-10
IL120382A0 (en) 1997-07-13
SK281530B6 (sk) 2001-04-09
RU2176912C2 (ru) 2001-12-20
PL188444B1 (pl) 2005-02-28
NO971206L (no) 1997-09-26
IN187337B (es) 2002-03-30
HUP9700589A2 (en) 1997-09-29
EG24198A (en) 2008-10-14
EP0797991B1 (en) 2004-01-02
ATE257011T1 (de) 2004-01-15
TR199700190A2 (xx) 1997-10-21
CA2199778A1 (en) 1997-09-25
CN1090018C (zh) 2002-09-04
SK30197A3 (en) 1997-10-08
ES2210454T3 (es) 2004-07-01
PT797991E (pt) 2004-05-31
HUP9700589A3 (en) 2001-03-28
ZA972403B (en) 1998-09-21
NZ314442A (en) 1999-06-29
PA8426401A1 (es) 2000-05-24
HU9700589D0 (en) 1997-05-28
HK1056686A1 (en) 2004-02-27
JP4771565B2 (ja) 2011-09-14
JP2008156374A (ja) 2008-07-10
AU727653B2 (en) 2000-12-21
NO320355B1 (no) 2005-11-28
SV1997000015A (es) 1997-08-13
CY2442B1 (en) 2004-11-12
HU224617B1 (hu) 2005-11-28
KR101096512B1 (ko) 2014-11-28
NO971206D0 (no) 1997-03-14
DE69727000T2 (de) 2004-06-09
AU1640097A (en) 1997-10-02
PL195564B1 (pl) 2007-10-31
KR970064599A (ko) 1997-10-13
DE69727000D1 (de) 2004-02-05
UA44904C2 (uk) 2002-03-15
MX9701873A (es) 1997-09-30
NO20050379L (no) 1997-09-26
AR006519A1 (es) 1999-09-08
CN1403077A (zh) 2003-03-19
BR9701304A (pt) 1998-09-29
CO4761054A1 (es) 1999-04-27
PL318954A1 (en) 1997-09-29
CA2199778C (en) 2005-12-20
TW493993B (en) 2002-07-11

Similar Documents

Publication Publication Date Title
UY24613A1 (es) Formula de liberacion controlada que comprende venlafaxina
AR014012A1 (es) Formula de liberacion prolongada
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
NO20053105L (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
MY142403A (en) Oral dosage forms for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
DE60320039D1 (de) Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit
ATE199495T1 (de) Pharmazeutische zubereitung zur direktverpressung
ECSP972046A (es) Formula de liberacion prolongada
ES2172179T3 (es) Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.
ECSP982704A (es) Formula de liberacion prolongada
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
BR9912260A (pt) Emplastro contendo um sistema terapêutico transdérmico e dose única para ministração
SE9700868D0 (sv) Kalciumkomposition
ES2082524T3 (es) Medicamento de liberacion retardada que contiene un derivado de dihidropiridina en forma de nanosol y su preparacion.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170710